Pipex Pharmaceuticals to Present at Acumen BioFin Rodman &Amp; Renshaw 4th Annual Global Healthcare Conference

Pipex Pharmaceuticals, Inc. (OTCBB: PPEX), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced that it will present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco on May 15, 2007, at 8:20 a.m. Central European Time. Steve H. Kanzer, chairman and chief executive officer, will make the presentation.

A live webcast will be available from the conference, and may be accessed through Pipex’s website at www.pipexpharma.com The webcast will be archived at the Company’s website for 30 days.

About Pipex Pharmaceuticals, Inc.

Pipex Pharmaceuticals, Inc. (“Pipex”) is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases. Pipex’s strategy is to exclusively in-license proprietary, clinical-stage drug candidates and complete the further clinical testing, manufacturing and regulatory requirements sufficient to seek marketing authorizations via the filing of New Drug Applications (NDAs) with the FDA in the U.S. and Marketing Application Authorizations (MAAs) with the European Medicines Evaluation Agency (EMEA). For further information, please visit, www.pipexpharma.com.

 For Further Information Contact:  Steve H. Kanzer, CPA, Esq. Chairman and Chief Executive Officer (734) 332-7800  Thomas Redington (Investor Relations) Redington Inc. 203-222-7399 www.redingtoninc.com

SOURCE: Pipex Pharmaceuticals, Inc.